CardioNet granted U.S. patent for “Biological Signal Management”

CardioNet, Inc. (NASDAQ: BEAT) announced today that the U.S. Patent and Trademark office has granted patent number 7,587,237 (“Biological Signal Management”) to CardioNet. The patent includes certain systems and techniques utilized by the Company’s Mobile Cardiac Outpatient Telemetry™ (MCOT™) system that automatically processes complex physiological information to make it useful for clinical decisions. This is the 15^th U.S. Patent that has been issued to CardioNet.

Randy Thurman, CardioNet Chairman, President and CEO, commented, “A key to success in delivering wireless medicine is rooted in our ability to distill the wide variety of information collected from sensors on the body and make that data useful for clinicians or other healthcare providers. With MCOT™, we provide electrocardiogram and trended heart rate data to physicians in order for them to make clinically relevant decisions. The issuance of this patent demonstrates our continued focus on innovation for applications in wireless medicine. Establishing and defending our extensive patent portfolio is key to our long-term strategy. This newly issued patent reinforces CardioNet’s position as the pioneer and technology leader in mobile cardiac outpatient telemetry.”

The issued patent abstract states: Systems and techniques for managing biological signals. In one implementation, a method includes receiving a cardiac biological signal that includes information describing events, determining a merit of each event based on one or more of a severity of a cardiac condition associated with the event and a quality of the event, and handling a subset of the events that meet a merit criterion. The subset can be handled for medical purposes.